Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be ...

CORAL GABLES, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for

Related Keywords

Singapore ,Canada ,United States ,American ,America ,Patrickj Mcenany ,David Morrell ,David Schull Russo ,Lambert Eaton ,Catalyst Pharmaceuticals Inc ,Health Canada ,American Cancer Society ,Global Health ,Marketing At Catalyst Pharmaceuticals ,Exchange Commission ,Health Services ,Investor Contact Mary Coleman Catalyst Pharmaceuticals Inc ,Health Economics ,Lung Cancer ,International Association ,Real World ,Lambert Eaton Myasthenic Syndrome ,Small Cell Lung Cancer ,North America ,Duchenne Muscular ,Fast Track ,Catalyst Pharmaceuticals ,Full Prescribing ,Safety Information ,Full Prescribing Information ,Key Statistics ,Rev Dis Primers ,Clin Oncol ,Thorac Oncol ,Annual Report ,Contact Mary Coleman Catalyst Pharmaceuticals ,Contact David Schull Russo Partners ,Glems ,Small Cell ,Ncology ,Irdapse ,Epilepsy ,Rare Disease ,Neuromuscular ,Eurology ,Muscle Weakness ,Myasthenia ,Autoimmune ,Dancer ,Young ,Prescription Drugs ,Medical Research ,Medication ,Health ,